Longeveron puts itself up for review after heart-defect cell therapy trial falls short

Longeveron's lead asset now has an uncertain route to market, and the company itself may not stay independent. Alongside third-quarter results on 12 November 2026, the cell therapy developer said it has launched a review of strategic alternatives, a process that could end in a sale or merger. Lucid Capital Markets has been appointed to advise.

The trigger was the Phase 2b ELPIS II study of laromestrocel in infants born with hypoplastic left heart syndrome (HLHS). The trial did not achieve its primary endpoint, right ventricular ejection fraction (RVEF). Longeveron has asked the US Food and Drug Administration for a meeting to discuss what happens next for the programme.

The data are not wholly negative. Major adverse cardiac events were lower among treated patients: one event, compared with eight in patients on standard of care. But because that count comes from a study that missed its main goal, it is difficult to read as confirmatory evidence, and how regulators view it is the open question the FDA meeting is meant to address.

The company also said it has put cash conservation measures in place. The information available does not give the size of the trial, the statistical weight of the MACE difference, a date for the FDA meeting or the company's cash position, so the runway for any further development cannot be assessed from what has been disclosed.